CLINICAL OUTCOMES EverFlex Self-expanding Peripheral Stent


DURABILITY II is the first controlled study to focus on treating long, complex lesions and to specifically test the performance of a single long stent in the superficial femoral artery. Read more about the DURABILITY II clinical study in these published, peer-reviewed  journal articles.

DURABILITY II - primary 3 year

A Single Stent Strategy in Patients with Lifestyle Limiting Claudication:  3-Year Results from the DURABILITY II Trial

Rocha-Singh KJ1, Bosiers M2, et al. Catheter Cardiovasc Interv. 2015 Jul;86(1):164-70.

DURABILITY II - gender 1 year

The Impact of Sex on Angioplasty and Primary Stenting for Femoropopliteal Occlusive Disease: Results of the DURABILITY II Trial.

Tadros RO, Faries PL, et al. Ann Vasc Surg. 2014 Jan;28(1):1-9.

DURABILITY II - gender 3 year

Intermediate Outcomes of Femoropopliteal Stenting in Women: 3-Year Results of the DURABILITY II Trial.

Han DK, Faries PL, et al. Ann Vasc Surg. 2016 Jan;30:110-17. 

DURABILITY 200 - long lesions

Results of the Protégé EverFlex 200-mm-long Nitinol Stent (ev3) in TASC C and D Femoropopliteal Lesions.

Bosiers M, Deloose K, et al. J Vasc Surg. October 2011, 54(4):1042-50.